dc.description.abstract |
This research project deals with the elaboration and evaluation of
coacervation technique for the microencapsulation of single drug (nimesulide)
and/or in combination (nimesulide and tizanidine) using non-biodegradable
and biodegradable polymers and physicochemical evaluation of prepared
Aims
and objectives
microparticles. The coacervation inducing methods adopted were temperature
change, pH change and non-solvent addition. The polymers employed were
non-biodegradable (ethylcellulose and hydroxypropylmethylcellulose) and
biodegradable
[Chitosan
and
poly(lactide-o-glycolic
acid)].
Various
microparticulate formulations were prepared by varying the ratio of drug to
polymer.
Firstly, EC microparticles were prepared using coacervation technique induced
by temperature change, to sustain the release of nimesulide and study the
effect of various formulation variables. Secondly, floating microparticles of
nimesulide using HPMC were prepared via coacervation non-solvent addition
technique to provide a mean of getting low dosage for prolonged periods and
to avoid direct contact with mucosa to minimize the irritant effect of drug on
the stomach. Thirdly, nimesulide-chitosan microparticles were prepared by pH
change coacervation by using cross-linking agent glutaraldehyde. Fourthly,
nimesulide was also formulated as sustained release microcapsules using
biodegradable polymer PLGA as the retardant material by non-solvent
addition coacervation method. Fifthly, nimesulide was formulated as novel
dual coated microparticles using chitosan and EC as encapsulating materials
for its improved delivery to the intestine and to prevent gastric irritation and
to increase compliance of patient. For dual coating, the coacervation
techniques adopted for CTN and EC were pH change and thermal change,
respectively. Sixthly, the microparticles for concurrent delivery in combined
dosage of nimesilde and tizanidine to maintain a constant therapeutic
concentration in plasma that may increase patient’s compliance and to
improve the efficacy were prepared using coacervation-thermal change
technique.
The prepared microparticles with different drug/polymer ratios were
characterized by micromeritics, SEM, FTIR, XRD, dissolution and thermal
studies. In-vitro, release profiles of prepared microparticles were studied
using USP XXIV dissolution apparatus I and II, respectively in 900 ml
phosphate buffer pH 6.8 at 75 rpm maintained at 37°C. Release profiles were
evaluated by model-dependent as well as model independent approaches.
Aims
and objectives
High Performance Liquid Chromatography was used for in-vivo studies of
marketed tablets and EC (with residual concentration very below toxic level
for cyclohexane and n-hexane) and chitosan microparticles (with residual
concentration very below for glacial acetic acid and glutaraldehyde). A reverse
phase C18 column was used. The mobile phase composition was acetonitrile-
methanol-15 mM potassium dihydrogen phosphate buffer (30:20:50), the
buffer pH was adjusted with potassium hydroxide to 7.8. It was passed
through a 0.4 μm filter before use. The flow rate was 1 ml/min at 30 oC and
run time was 7 minutes. The detection was performed at 404 nm.
Finally, the in-vitro in-vivo correlations (IVIVC) were established between the
in-vitro and in-vivo data obtained from EC and chitosan formulations using
Wagner-Nelson equation.
All microparticles were discrete, yellowish in colour and irregular in
morphology with good stability, fine rheological properties and good
encapsulation efficiencies. Percentage product yields were greater than 80%
for EC and HPMC formulations. No strong chemical interaction was observed
in between drug and polymers as evident from FTIR, XRD and thermal
analyses. It was found that release behaviour was biphasic and directly
proportional to polymer concentration. According to the plots linearity drug
release profile from all the formulations was explained in the order Higuchi’s
equation > zero order > first order. The method of drug release from all
formulations was anomalous diffusion.
It was found that pH change coacervation is an efficient method to
encapsulate biopharmaceutical class II drugs into different polymers like EC,
HPMC, chitosan and PLGA. The EC formulations (M1 and M2) and
conventional tablet (Nimarin®) exhibited good linear IVIVC (R2 = 0.9220,
0.9124, 0.8728, respectively) as compared to M3 (R2 = 0.9449). The results
substantiate the success of this mathematical simulation study and encourage
researchers to conduct biowaiver studies for other BCS class II drugs. The
regression coefficients of IVIVC plots for chitosan formulations (M1, M2, M3)
and conventional tablet were 0.8611, 0.9223, 0.9328 and 0.904, respectively. |
en_US |